CTLA4 and non-small cell lung carcinoma: The effective use of either PD-1 or PD-L1 inhibitors, alone or combined with chemotherapy or anti-CTLA-4 agents, has been observed in NSCLC and SCLC patients with BM [6,12,13,14].